Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study

Authors

  • Rolf Gedeborg Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Hans Garmo Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Translational Oncology and Urology Research (TOUR), King's College London, Guy's Hospital, London, UK
  • Camilla Thellenberg-Karlsson Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
  • Giuseppe Fallara Division of Experimental Oncology, Unit of Urology URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita‐Salute San Raffaele University, Milan, Italy
  • Johan Styrke Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
  • Ingela Franck Lissbrant Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Pär Stattin Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

DOI:

https://doi.org/10.1080/0284186X.2021.2023215

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-03-04

How to Cite

Gedeborg, R., Garmo, H., Thellenberg-Karlsson, C. ., Fallara, G., Styrke, J., Franck Lissbrant, I., & Stattin, P. (2022). Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncologica, 61(3), 328–332. https://doi.org/10.1080/0284186X.2021.2023215

Issue

Vol. 61 No. 3 (2022): Acta Oncologica

Section

Articles